Neurodegenerative disease

This Phase 1 trial tests an experimental vaccine called AV-1980R that targets tau protein, a key player in Alzheimer's disease. The study enrolls 48 cognitively healthy adults aged 65-80 who have biological signs of early Alzheimer's. Researchers will check if the vaccine is safe…

This study tests a new oral polio vaccine (nOPV3) in healthy young children, infants, and newborns in Panama. The goal is to see if it is safe and triggers a strong immune response compared to the current vaccine. About 1,500 participants will receive either the new or existing v…

This Phase 3 trial tests trontinemab, an antibody given by IV, in 800 people with early Alzheimer's (mild cognitive impairment to mild dementia). Half get the drug, half get a placebo, for 72 weeks. The goal is to see if it slows decline in memory, thinking, and daily activities.

This early-stage trial is testing whether a personalized natural killer (NK) cell therapy called SNK01 is safe and might help people with moderate Alzheimer's disease. The treatment is made from each patient's own immune cells and given as an IV infusion every three weeks for up …

This study compares two versions of the drug ocrelizumab given as a shot under the skin in people with multiple sclerosis. The goal is to see if the new test version works the same as the current one. About 182 participants with relapsing or primary progressive MS will take part.

This phase 3 trial is testing whether the drug pridopidine can slow the progression of amyotrophic lateral sclerosis (ALS) in 500 adults. Participants will take either pridopidine or a placebo daily for 48 weeks, followed by an open-label extension where everyone receives the dru…

This study tests whether clemastine fumarate, a common allergy medicine, can help repair the protective coating around nerves (myelin) in people with multiple sclerosis. About 74 adults with relapsing-remitting MS will receive either the drug or a placebo, and advanced MRI scans …

This phase 2 trial tests whether NLY01, a drug similar to those used for diabetes, can slow brain and retinal shrinkage in people with multiple sclerosis. About 120 adults with stable MS will receive either NLY01 or a placebo for 96 weeks. The main goal is to see if the drug redu…

This phase 2 trial tests a powerful mix of short-course radiation, chemotherapy (mFOLFOX6), an immunotherapy (PD-1 antibody), and a targeted drug (cetuximab or bevacizumab, depending on genetic markers) in people with high-risk rectal cancer that is mismatch repair proficient (pM…

This clinical trial tests an oral drug called SKY-0515 in 400 adults with Huntington's disease. The goal is to see if it can lower harmful proteins linked to the disease and improve symptoms like movement and thinking. Participants take the drug or a placebo daily for 18 months.

This early-stage study is testing a new drug called RO7121932 in 129 people with multiple sclerosis (MS). The goal is to check if the drug is safe and how the body handles it when given as a single or multiple doses, either through a vein or under the skin. Participants are not o…

This Phase 3 trial tests whether privosegtor, a neuroprotective drug, can improve vision recovery in people having their first episode of optic neuritis. About 210 adults aged 18 to 50 will receive either privosegtor or a placebo, both alongside standard steroid treatment. The ma…

This study tests an experimental drug, fosigotifator, in adults and children with Vanishing White Matter disease, a rare genetic brain disorder. The main goals are to check the drug's safety and how the body processes it. About 50 participants will take the drug for up to 201 wee…

This Phase 3 trial tests whether adding immunotherapy and a targeted drug to short-course radiotherapy and chemotherapy improves outcomes for people with high-risk rectal cancer. About 204 participants will receive either the standard treatment or the intensified combo. The study…

This early-phase trial is testing a new treatment called KITE-363 for people with certain autoimmune nerve diseases that have not responded to standard therapies. KITE-363 is a type of CAR T-cell therapy that uses a patient's own immune cells, modified to target and attack faulty…

This early-stage trial tests a new treatment called CC-97540, which uses a patient's own immune cells engineered to target and destroy harmful immune cells. The study includes 120 people with relapsing or progressive multiple sclerosis or refractory myasthenia gravis. The main go…

This study tests two different doses of an intravenous immune globulin (IGIV 10%) as maintenance therapy for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder causing weakness and numbness. About 161 participants will receive either a higher o…

This study is testing an experimental drug called DNL628 in people with early-stage Alzheimer's disease. The main goal is to see if the drug is safe and how the body processes it. About 68 participants will receive either DNL628 or a placebo. This is an early-phase trial, so it f…

This Phase 3 trial tests an oral drug called orelabrutinib against a placebo in about 990 people with non-active secondary progressive multiple sclerosis (MS). The goal is to see if the drug can delay worsening disability over 24 to 60 months. Participants are randomly assigned t…

This early-stage study tests a new drug called RO7812653 in 50 people with early Alzheimer's disease. The main goal is to check if the drug is safe and how the body handles it. Participants receive a single dose injected into the spine and are closely monitored for side effects.

This early-phase trial tests a single dose of YTB323, a CAR-T cell therapy, in 28 adults with non-active progressive multiple sclerosis. The study aims to check safety and track disability changes over time. Participants must be 18–60 and able to undergo lumbar punctures and MRIs…

This study tests whether a special probiotic supplement can change fat-related molecules in the blood of people with ALS and frontotemporal dementia (FTD). Researchers will compare those taking the probiotic to those taking a placebo over 24 weeks. The goal is to see if the probi…

This study tests a single dose of GB221, a gene therapy that delivers a working SMN1 gene, in infants aged 2 weeks to under 12 months with spinal muscular atrophy (SMA) Type 1. The goal is to see if it is safe and helps improve motor function. The trial includes both symptomatic …

This early study tests whether a smart brain implant can help people with spinocerebellar ataxia type 6, a condition that causes trouble with balance and coordination. Five adults will get the implant, which records brain signals and adjusts stimulation automatically. The goal is…

This study tests whether injecting a person's own bone marrow stem cells into or near the eye can help treat various retinal and optic nerve diseases, including age-related macular degeneration, retinitis pigmentosa, and glaucoma. Participants receive stem cell injections via dif…

This phase 3 trial tests whether the oral drug orelabrutinib can slow disability progression in people with primary progressive multiple sclerosis (PPMS). About 705 adults aged 18–60 with PPMS will receive either orelabrutinib or a placebo for up to 5 years. The study measures ti…

This early-stage study tests a new drug called RG6496 in people who carry the gene for Huntington's disease. The main goal is to check if the drug is safe and how the body handles it. About 40 participants will receive a single dose injected into the spine, with some getting a pl…

This early-stage study tests a new medicine called PYC-001, given as an injection into the eye, for people with a rare genetic eye disease (autosomal dominant optic atrophy) caused by a change in the OPA1 gene. The main goal is to check the safety of different doses and schedules…

This study tests whether a combination of two drugs, KarXT and KarX-EC, can improve cognitive impairment in people with mild to moderate Alzheimer's disease. About 586 participants will receive either the drug combo or a placebo. The trial measures changes in thinking, daily func…

This study tests an experimental drug called VHB937 in people with early Alzheimer's disease. About 400 participants will receive either the drug or a placebo by infusion over 72 weeks. The goal is to see if the drug can slow down memory and thinking problems. Researchers will al…

This phase 3 trial compares a new drug, BMS-986365, against standard treatments (docetaxel or other hormone therapies) in 960 men with metastatic castration-resistant prostate cancer that has stopped responding to hormone therapy. The main goal is to see if the new drug delays ca…

This study tests donanemab, an experimental drug, against a placebo in 140 Chinese adults who show early signs of Alzheimer's risk. Participants receive the drug intravenously every few weeks for up to 3 years. The goal is to see if donanemab can delay memory loss and help mainta…

This study tests whether starting non-invasive ventilation (a breathing machine) earlier than usual helps people with ALS. Researchers will use a prediction tool to find those at high risk of breathing problems within 6 months. 48 participants will be randomly assigned to early N…

This phase 3 trial is testing whether a daily pill called remibrutinib works as well as the standard infusion or injection ocrelizumab for people with relapsing multiple sclerosis. About 360 adults aged 40–70 who are stable on ocrelizumab will either switch to remibrutinib or sta…

This study follows 30 adults in Taiwan with relapsing-remitting multiple sclerosis who are starting fingolimod (Gilenya), a daily pill that helps control the disease. Over 12 months, researchers will watch for specific side effects like slow heart rate, vision problems, liver iss…

This study is testing whether stem cells taken from a person's own bone marrow and then given back through the veins and nose can improve brain and nerve function. It includes 500 people with various conditions like stroke, Parkinson's, Alzheimer's, and nerve damage. The goal is …

This study tests whether people with Alzheimer's who already took the drug donanemab benefit from getting it just once a year. About 550 volunteers who finished a previous donanemab study will receive either the drug or a placebo for up to 2.5 years. Researchers will track change…

This study tests an experimental drug called MK-2214 in 340 people with early Alzheimer's disease. The goal is to see if it can slow the buildup of a harmful protein called tau in the brain, which damages brain cells. Participants will receive either the drug or a placebo, and re…

This study tests a new drug called tulmimetostat combined with standard hormone therapies (darolutamide or abiraterone) in men whose prostate cancer has spread but still responds to hormone treatment. The goal is to see if the combination is safe and works better than standard ca…

This study tests a drug called LHP588 in 300 people with mild-to-moderate Alzheimer's who also have a gum infection from P. gingivalis bacteria. The drug aims to target that bacteria to slow down memory and thinking decline. Participants take a daily capsule for up to 48 weeks, a…

This study tests whether adding a new drug (RO7268489) to the standard MS treatment ocrelizumab can slow disability progression in adults with progressive multiple sclerosis. About 360 participants will receive either the new drug or a placebo, and researchers will track walking …

This early-stage trial is testing whether stem cells taken from donated fat tissue are safe when given through an IV to people with mild to moderate Alzheimer's disease. Nine participants will receive increasing doses of the cells and be monitored for side effects over six months…

This expanded access program offers the drug tazbentetol to adults with ALS who cannot join other clinical studies. Participants take one 300 mg pill by mouth each day. The program aims to check the drug's safety and whether it helps control the disease.

This study tests the long-term safety of a drug called LY4256984, given via spinal injection, in people with ALS. It includes 32 participants who completed an earlier study and will be followed for about 96 weeks. The main goal is to see how many people have serious side effects …

This study tests an experimental drug called ABBV-1758 in about 210 people with Alzheimer's disease. The drug is given by IV or injection every 4 weeks for 24 weeks. Researchers are checking if it is safe and whether it can reduce amyloid plaques in the brain, a hallmark of Alzhe…

This study tests a new drug called ARO-MAPT-SC in healthy people and those with early Alzheimer's. The goal is to check if it is safe and how the body processes it. Participants receive either the drug or a placebo by injection under the skin. The trial is still in early stages, …

This phase 3 trial tests an experimental drug called sepofarsen in 32 people with Leber congenital amaurosis (LCA), a rare genetic condition that causes severe vision loss from birth. The drug is injected into one eye, while the other eye gets a placebo, to see if it safely impro…

This phase 2 trial tests whether a 3-day course of high-dose corticosteroids (methylprednisolone or prednisone) can help heal ring-enhancing brain lesions in people with multiple sclerosis. Thirty adults with MS and a specific type of active lesion will be randomly assigned to re…

This early-stage trial is testing a new way to give ocrelizumab (Ocrevus) for multiple sclerosis — as a simple shot under the skin instead of a long IV infusion. About 75 adults with MS will receive increasing doses to see if the new form is safe and tolerable. If it works, it co…

This phase 2 trial tests whether tofersen, a drug already approved for a specific type of ALS, can help people with ALS who do not have the SOD1 gene mutation. Thirty adults will receive the drug via spinal injections over 24 weeks. Researchers will measure changes in nerve damag…

This study looks at whether people with early relapsing multiple sclerosis (MS) can stop taking ocrelizumab (Ocrevus) after two years without their disease coming back. All 123 participants will receive ocrelizumab for the first two years. Then, some will switch to a placebo whil…

This study looks at the long-term safety of an experimental drug called LY4256984 for people with ALS. It enrolls up to 32 participants who have completed a prior ALS trial. The study will follow them for at least 96 weeks to see how well the drug is tolerated over time.

This Phase 3 trial tests whether a simple injection of frexalimab every 4 weeks works as well as the standard IV infusion for adults with relapsing or non-active progressive multiple sclerosis. About 160 participants will be randomly assigned to one of the two methods. The study …

This study looks at whether people with relapsing-remitting multiple sclerosis (RRMS) who are over 40 and have been stable on strong anti-CD20 drugs for at least 3 years can safely switch to milder treatments. The goal is to see if this de-escalation approach prevents disease act…

This study tests a new drug called AZD9750, alone or with another drug (saruparib), in 300 men with metastatic prostate cancer that has progressed despite standard treatments. The goal is to check safety, find the right dose, and see if it can lower PSA levels, a marker of cancer…

This Phase 3 trial tests whether the drug votoplam can slow the progression of Huntington's disease in people with early symptoms. About 770 adults aged 21 to 70 with a confirmed genetic diagnosis will receive either votoplam or a placebo. The main goal is to see if votoplam pres…

This trial tests a gene therapy for metachromatic leukodystrophy (MLD), a rare and life-threatening genetic disorder that damages the nervous system. The treatment uses a lentivirus to deliver a working copy of the ARSA gene directly into the spinal fluid and bloodstream. Up to 1…

This study tests whether a weekly under-the-skin antibody treatment (XEMBIFY) provides similar blood levels as a standard IV infusion (Gamunex-C) given every 3 weeks in people with CIDP, a chronic nerve disorder. About 40 adults who are stable on IVIG will first receive Gamunex-C…

This study tests an experimental drug called NIO752 in 300 people with progressive supranuclear palsy (PSP), a rare brain disorder that affects movement and balance. Participants are randomly assigned to receive either the drug or a placebo. After the main study, everyone can rec…

This Phase 3 study tests whether the drug remibrutinib can slow disability worsening in people with secondary progressive multiple sclerosis (SPMS). About 1,275 adults aged 18-65 with SPMS and recent disability progression will receive either remibrutinib or a placebo. The main g…

This early-stage study tests a new drug called VTx-002 in 12 people with ALS. The main goal is to check if the drug is safe and tolerable when given as a single injection into the fluid around the brain and spinal cord. Researchers will also look for signs that the drug might slo…

This early-stage trial tests a brain-computer interface called BrainGate for people with paralysis from conditions like ALS or spinal cord injury. A small sensor is placed in the brain to interpret movement-related signals, allowing users to control a tablet computer just by thin…

This study tests an experimental drug called ALN-SOD in people with ALS caused by a mutation in the SOD1 gene. The drug is given via spinal injection to target the root cause of the disease. The main goal is to check safety, but researchers will also measure effects on biomarkers…

This early-phase trial is testing a gene therapy called SGT-212 for Friedreich's ataxia, a rare genetic disease that damages the nervous system. Ten adults with the condition will receive the therapy through an injection into the brain and a vein. The main goal is to see if it is…

This study tests an experimental oral drug called KDS2010 in people with mild cognitive impairment or mild dementia due to Alzheimer's disease. Participants take either a low dose, a higher dose, or a placebo daily for 24 weeks. Researchers measure changes in memory, thinking, an…

This study tests an investigational drug called LTX-002 in people with amyotrophic lateral sclerosis (ALS). The drug is designed to target a specific genetic message linked to the disease. The main goal is to check the drug's safety and tolerability, and to see how it moves throu…

This study tests an experimental drug called NB-4746 in 80 people with ALS. The goal is to see if it is safe, how it moves through the body, and whether it can reduce a marker of nerve damage (NfL) in the blood. Participants are randomly assigned to receive either NB-4746 or a pl…

This phase 2 trial tests whether donanemab, an antibody given by IV, can slow worsening of thinking and daily function in people with early cognitive decline and Lewy body dementia. The study enrolls 350 participants who also have signs of two brain proteins (amyloid and alpha-sy…

This study tests the long-term safety and effectiveness of a daily medication called nizubaglustat in people with two rare genetic diseases that affect the brain and body. About 21 participants who were in a previous study or who have been on a similar drug (miglustat) will take …

This study tests an oral drug called nizubaglustat in children and teens with rare genetic disorders (GM1, GM2 gangliosidosis) that damage the brain and nerves. The goal is to see if the drug can slow disease progression and improve movement and coordination. About 75 participant…

This study tests whether changes in spinal fluid biomarkers can predict which drug or drug combination works best for people with progressive multiple sclerosis (MS). Participants will take one or two of five drugs (cilostazol, leucovorin, pirfenidone, dantrolene, or pioglitazone…

This Phase 3 trial tests an oral drug called nizubaglustat (AZ-3102) in people aged 4 and older with Niemann-Pick type C disease, GM1 gangliosidosis, or GM2 gangliosidosis. The study lasts 18 months and compares the drug to a placebo to see if it is safe and can slow disease prog…

This study tests an experimental oral drug, TEV-56286, in 350 adults with multiple system atrophy (MSA), a rare and progressive brain disorder. Participants will receive either the drug or a placebo for 48 weeks to see if it slows disease worsening and is safe. The goal is to fin…

This study is testing the long-term safety of an oral drug called Emrusolmin (TEV-56286) in 200 adults with multiple system atrophy (MSA), a rare and serious brain disorder. Participants who completed a prior trial will take the drug for about 100 weeks. The main goal is to see h…

This study is for people who have both an autoimmune disease (like rheumatoid arthritis, lupus, or multiple sclerosis) and an advanced cancer that has spread or cannot be removed by surgery. It tests the safety and effectiveness of the immunotherapy drug nivolumab, given alone or…

This early study tests a new treatment called azercabtagene zapreleucel (azer-cel) for people with B-cell mediated autoimmune disorders like multiple sclerosis and neuromyelitis optica. The treatment uses a patient's own immune cells that are modified in a lab to target and destr…

This Phase 3 trial is testing a modified dosing schedule of ublituximab (BRIUMVI) in 800 people with relapsing multiple sclerosis. The study has three parts: one open-label part to see if the new regimen reduces brain lesions, a placebo-controlled part to measure drug levels, and…

This study tests a drug called salanersen in babies who have a genetic diagnosis of spinal muscular atrophy (SMA) but no symptoms yet. The drug helps the body make more of a protein that is missing in SMA, which is needed for muscles to work. Researchers want to see if starting t…

This early-phase trial tests whether combining interleukin-2 (IL-2) with semaglutide (a diabetes drug) can safely reduce harmful inflammation in the brains of people with Alzheimer's disease. The study will enroll 30 adults aged 50–86 with mild-to-moderate Alzheimer's. Participan…

This study tests an experimental drug, dazucorilant, in 279 adults with ALS (Lou Gehrig's disease). The goal is to see if the drug can slow the loss of muscle function and improve quality of life over 24 weeks. Participants will receive either the drug or a placebo, and researche…

This Phase 2 trial tests an experimental mRNA therapy called mRNA-1195 in 180 adults aged 18 to 55 with relapsing multiple sclerosis. Participants receive either the mRNA shot or a placebo, and researchers monitor safety and measure new brain lesions on MRI scans over about 2.5 y…

This study tests a new drug called riliprubart against standard IVIg treatment in 160 adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder causing weakness and numbness. Participants currently on IVIg will be randomly assigned to receive either r…

This study tests whether omaveloxolone, a drug already approved for people 16 and older with Friedreich's ataxia, can safely help children aged 2 to 15. About 255 participants will first receive either the drug or a placebo for a year, then all will receive the drug for two more …

This study tests whether cannabidiol (CBD) can slow the progression of Alzheimer's disease in people aged 55-85 with mild cognitive impairment (early memory loss). Over 236 participants will receive either CBD or a placebo for a period, and researchers will measure changes in mem…

This phase 3 trial tests whether empasiprubart, given by IV infusion, can help adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder that causes weakness and disability. The study will enroll 160 participants. For the first 6 months, some get the …

This early study tests a nasal spray called foralumab in 5 adults with multiple system atrophy (MSA), a rare brain disease that gets worse over time. The goal is to see if the drug can reduce harmful brain inflammation and slow down symptoms like movement problems. Researchers wi…

This early-stage trial is testing a single injection of a gene therapy called INS1202, given into the spinal fluid, for people with ALS (Lou Gehrig's disease). The study includes 23 adults, some with a specific genetic mutation (SOD1) and some without known genetic causes. The ma…

This study tests whether a daily polyphenol supplement (like berry capsules) can slow cognitive decline in 300 older adults at risk for Alzheimer's. Participants take the supplement or a placebo for 12 months, providing blood, stool, and brain scans. The goal is to see if the sup…

This study tests a drug called riliprubart in 140 adults with chronic inflammatory demyelinating polyneuropathy (CIDP) that hasn't improved with standard care. Participants receive either riliprubart or a placebo for up to 111 weeks. The main goal is to see if the drug reduces di…

This early-stage study tests a new drug called ALN-5288 in 50 adults with mild cognitive impairment or dementia caused by Alzheimer's disease. The drug is given via a spinal injection and aims to safely reduce tau protein levels in the brain. The main goal is to check safety and …

This early-stage study tests an experimental drug called ALN-HTT02 in 66 adults with Huntington's disease. The drug is given as a single injection into the spine to see if it is safe and how it affects the body. The goal is to reduce levels of the harmful protein that causes the …

This study tests a new medicine called empasiprubart against the standard treatment (IVIg) for people with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disease that causes weakness and numbness. About 218 adults who have used IVIg before will receive either t…

This early-stage trial tests a drug called ALN-APP (mivelsiran) in 60 adults with mild cognitive impairment or mild dementia due to early-onset Alzheimer's disease. The drug is given via a spinal injection to see if it safely lowers certain proteins linked to Alzheimer's in the b…

This study follows about 215 adults with advanced Parkinson's disease who are switching from a pump medication to a new intestinal gel called LECIGON®. Researchers want to see if the gel reduces daily 'off' time—when symptoms return—over 12 months. Participants continue their usu…

This early-stage trial tests the safety and tolerability of a new drug called VX-670 in 52 adults with myotonic dystrophy type 1 (DM1), a genetic condition that causes muscle weakness and other problems. Participants receive either VX-670 or a placebo, and researchers will monito…

This study tests an oral drug called fenebrutinib in 12 children and adolescents aged 10 to 17 with relapsing multiple sclerosis. The goal is to see how the drug moves through the body, how safe it is, and whether it reduces new brain lesions seen on MRI. Participants can choose …

This Phase 2b study tests whether the drug IMVT-1402 can help adults with CIDP, a nerve disorder causing weakness and numbness. About 162 participants will receive either the drug or a placebo weekly for up to 52 weeks. The main goal is to see if the drug keeps the disease from w…

This Phase 3 trial tests whether trontinemab can slow down Alzheimer's in people with early symptoms like mild memory problems. About 800 volunteers will receive either the drug or a placebo by IV for 72 weeks. The study measures changes in thinking, daily function, and safety.

This study tests whether adding risdiplam, a daily oral medicine, can help children under 2 with spinal muscular atrophy (SMA) who stopped getting better or started declining after receiving gene therapy. The study will enroll 28 children and measure changes in motor skills over …

This study tests whether taking silkworm pupa powder daily for four months can improve thinking, daily living, and nutrition in people with Alzheimer's disease. About 300 participants will receive either the powder or a placebo. Researchers will track changes in memory, frailty, …

This study tests a drug called NPC-1 (made of two natural compounds) in 40 adults aged 55+ with early Alzheimer's, mild cognitive impairment, or subjective memory concerns. The goal is to see if it safely changes blood markers linked to Alzheimer's brain changes. Participants tak…

This study tests a brain-computer implant (Stentrode) for people with paralysis from motor neuron disease or similar conditions. The device is placed in a blood vessel near the brain and aims to let users control computers or assistive devices with thought. The trial focuses on s…

This phase 2 trial is testing whether an inhaled drug called cromolyn (PHENOGENE-1A) can help people with mild-to-moderate ALS when added to standard care. About 105 participants will receive either a low dose, high dose, or placebo for 24 weeks. Researchers will measure changes …

This study tests a new drug called SRP-1005 in 32 adults with Huntington's disease. It is the first time this drug is being tested in humans, so the main goal is to check safety and how the body processes the drug. Participants will receive either SRP-1005 or a placebo by injecti…

This study is testing several experimental treatments at the same time to see if they can slow down ALS, a disease that weakens muscles and gets worse over time. About 1,500 adults with early-stage ALS will take part. The goal is to find treatments that help people stay stronger …

This early-stage study tests a new drug called LY4006895 in healthy volunteers and people with early symptomatic Alzheimer's disease. The main goal is to check if the drug is safe and how the body processes it. The study has two parts: a single dose in healthy people and multiple…

This study tests an experimental drug called PrP-siRNA in 30 adults with symptomatic prion disease, a rare and fatal brain condition. The drug is given via a spinal injection and aims to reduce the harmful prion protein in the brain. The main goal is to check safety and find the …

This study tests whether the drug nipocalimab can delay or prevent relapses in adults with CIDP, a rare nerve disorder that causes weakness and numbness. Participants first receive nipocalimab, and those who improve are then randomly assigned to continue the drug or switch to a p…

This Phase 3 trial tests whether the drug claseprubart (DNTH103) can prevent relapses in adults with CIDP, a nerve disorder that causes weakness and disability. About 256 participants will receive either the drug or a placebo. The main goal is to see how long it takes for symptom…

This study tests the safety and feasibility of the BrainGate2 system, a brain-computer interface. Tiny sensors are placed in the brain area that controls movement, allowing people with tetraplegia (paralysis of all four limbs) to control a computer cursor or other assistive devic…

This early study tests whether a robot can safely perform microsurgery on deep neck lymph nodes in 15 people with mild-to-moderate Alzheimer's. The idea is that clearing blockages in these lymph nodes might help the brain remove harmful waste. The main goal is to check safety, no…

This study looks at two different doses of a medicine called Privigen in children aged 2 to 17 with a nerve disease called CIDP. The goal is to see which dose better prevents the disease from getting worse. About 30 children will take part, and the study is currently recruiting.

This study tests an experimental vaccine called ACI-24.060 in people with early Alzheimer's and non-demented adults with Down syndrome. The vaccine is designed to help the immune system clear amyloid plaques from the brain, which are linked to Alzheimer's. Researchers will check …

This early-phase study tests an experimental cell therapy called YTB323 in about 28 people with relapsing multiple sclerosis whose disease is still active despite taking strong medications. The goal is to see if YTB323 is safe and can control the disease. Participants receive a s…

This study tests whether adding a single infusion of human stem cells to standard antibody therapy can slow memory and thinking decline in people with mild Alzheimer's or mild cognitive impairment. Ten participants aged 55-90 who are already on antibody treatment will receive one…

This early-stage trial tests a drug called atipeksen for people with Ataxia-Telangiectasia (A-T), a rare genetic disease that affects movement and coordination. The drug is designed to fix a specific genetic error in the ATM gene and is given via spinal injection. The study will …

This study tests the drug ocrelizumab in 60 Chinese adults with two forms of multiple sclerosis (MS): relapsing MS and primary progressive MS. The goal is to see if it reduces relapses and controls disease activity. Participants receive ocrelizumab infusions, and researchers trac…

This early-stage trial is testing whether a nasal spray containing exosomes from umbilical cord stem cells is safe and might help people with mild to moderate Alzheimer's. The study involves 33 participants and will first test different doses, then compare the best dose to a plac…

This early-stage trial is testing a new treatment called AZD0120 for people with multiple sclerosis (MS) that has not responded to other therapies. AZD0120 is a type of immune cell therapy (CAR-T) designed to target and reset the immune system. The study will enroll 24 adults age…

This study tests a drug called lecanemab in 200 people with early-stage Alzheimer's. Participants receive either lecanemab or standard care for 24 months. Researchers use eye and brain scans along with memory tests to see if the drug slows the disease and to check for side effect…

This study tests whether a drug called leronlimab is safe for people with mild Alzheimer's or mild cognitive impairment. Twenty volunteers over age 50 will receive weekly injections for 12 weeks. Researchers will use brain scans and blood tests to see if the drug lowers brain inf…

This study tests a new biologic drug called ARGX-119 in children aged 5 to 17 with spinal muscular atrophy (SMA). About 60 participants will receive either ARGX-119 or a placebo by IV infusion for 24 weeks, alongside their usual SMA therapy. The goal is to find the best dose and …

This early study tests a single dose of GC012F CAR-T cell injection in 9 people with multiple sclerosis. The main goal is to check safety and tolerability, not yet to see if it works. Researchers will monitor side effects for up to 15 years and measure how the cells behave in blo…

This Phase 2 trial is testing an investigational drug called COYA 302 in 120 adults with ALS. The drug combines two immune-modulating agents to reduce inflammation that may damage nerves. Participants will receive either COYA 302 or a placebo for 24 weeks, with an option to conti…

This study tests a small device implanted on the vagus nerve in the neck to see if it can help repair myelin (the protective coating around nerves) in people with relapsing-remitting multiple sclerosis. About 60 adults aged 22–50 will take part. Two-thirds will receive active sti…

This study is testing the long-term safety and effectiveness of an experimental drug called CTI-1601 for people with Friedreich's ataxia, a rare genetic disease that affects movement and heart function. It includes about 85 adolescents and adults who have or have not taken the dr…

This study explores whether daily mindfulness practice, combined with heart rate biofeedback, can improve attention and memory in adults aged 50-70. Participants will practice breathing patterns that either increase or decrease heart rate swings. Researchers will measure changes …

This study tests a new treatment called MB-CART2019.1 for people with active multiple sclerosis (MS) that hasn't responded to other therapies. The treatment uses a patient's own immune cells, modified to target and attack harmful immune cells driving MS. The goal is to see if it …

This study tests whether a non-invasive brain stimulation technique called repetitive transcranial magnetic stimulation (rTMS) can slow cognitive decline in people with early Alzheimer's disease. The treatment targets a key brain region affected by Alzheimer's. Fifty-five partici…

This early-phase study tests a new treatment called RD06-05, which uses specially engineered immune cells (CAR-T cells) to target and calm the immune system in people with neurological autoimmune diseases like multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinat…

This early study tests a brain-computer implant placed through blood vessels to help people with ALS control external devices using their thoughts. Ten participants with ALS and arm weakness will be followed for safety and device function. The goal is to restore some independence…

This study tests a surgical procedure called deep cervical lymphatic venous anastomosis (DC-LVA) in 376 people with moderate-to-severe Alzheimer's disease. The surgery connects lymph vessels in the neck to veins, aiming to improve drainage of waste from the brain. Researchers wil…

This early-stage study tests whether it is safe to combine a drug called etanercept with repeated ultrasound sessions to temporarily open the blood-brain barrier in people with mild Alzheimer's disease. The goal is to let more of the drug reach the brain to reduce inflammation. O…

This early-phase trial is testing a new cell therapy called QH103 for people with severe autoimmune diseases like multiple sclerosis and myasthenia gravis that haven't responded to standard treatments. The therapy uses specially engineered immune cells to target and attack the fa…

This study is testing a new knee implant (Univation XF Pro) in 150 people with knee arthritis. The goal is to see how well the implant works and how safe it is over several years. Participants will have their knee function, pain, and quality of life tracked using questionnaires a…

This early-stage study tests a new treatment called HBI0101 CAR T for people with severe autoimmune diseases like lupus, multiple sclerosis, and rheumatoid arthritis that haven't improved with standard treatments. The main goal is to find a safe dose and check for side effects in…

This Phase 2 trial tests whether ambroxol, a common cough medicine ingredient, can slow cognitive decline and improve symptoms in people with early dementia with Lewy bodies. 180 participants will receive either ambroxol or a placebo for 18 months. The study measures changes in t…

This study tests an experimental drug called TP04HN106 in 60 people with ALS. Half receive the drug, half receive a placebo (saline), and all take riluzole tablets as standard care. The goal is to see if the drug is safe and can slow the decline in physical function measured by t…

This study tests a new gene therapy called SPK-10001 for people with Huntington's disease. It involves a one-time infusion into specific areas of the brain. The main goal is to see if it is safe and if it can slow down the worsening of movement and daily function. About 53 adults…

This Phase 2 trial tests whether fasudil, a drug already used in Japan and China for brain blood vessel spasms, can improve memory and brain function in people with early Alzheimer's disease. Two hundred participants will receive either fasudil or a placebo for 12 months, with re…

This study is testing whether the drug risdiplam can improve motor skills in children under 2 with spinal muscular atrophy (SMA) who have already received gene therapy. The 28 participants will take risdiplam by mouth, and researchers will measure changes in their gross motor ski…

This study tests whether giving ALS patients 20% more calories than their body needs (via a feeding tube) can slow the disease. Researchers will measure a nerve damage marker in the blood over 6 months. 76 adults with ALS who already use a feeding tube will be randomly assigned t…

This study tests whether 6 months of supervised aerobic exercise can improve fitness, brain health, and memory in adults aged 65 and older with mild cognitive impairment or early Alzheimer's disease. Participants will exercise, undergo memory tests, and have MRI scans over a year…

This study tests an investigational drug called KarXT to see if it can prevent the return of psychosis (like hallucinations or delusions) in people with Alzheimer's disease. About 410 participants aged 55-90 will receive either KarXT or a placebo for 38 weeks. The main goal is to…

This study tests whether the sleep medication lemborexant (Dayvigo) can reduce levels of amyloid-beta and tau proteins in the blood and spinal fluid of older adults. These proteins are linked to Alzheimer's disease. The trial will enroll 201 healthy volunteers aged 65 and older, …

This study tests whether an ultra-high-caloric diet made almost entirely of fat can help people with ALS live longer and slow the disease. Researchers will compare the diet to a low-fat placebo in 392 participants. The main goal is to see if the diet extends survival without the …

This study compares two treatments for CIDP, a nerve condition that causes weakness and numbness. It involves 20 adults who did not get better with steroids. One group receives a blood-filtering procedure called immunoadsorption, and the other receives standard antibody infusions…

This study tests a drug called apitegromab in children under 2 years old who have spinal muscular atrophy (SMA), a genetic condition that causes muscle weakness. The drug works by blocking a protein that limits muscle growth. Researchers want to see if adding apitegromab to stand…

This phase 2 trial is testing whether sargramostim, a drug already approved to stimulate bone marrow, is safe and effective for people with mild-to-moderate Alzheimer's disease. Over 6 months, 42 participants will receive either the drug or a placebo. The study will monitor side …

This study looks at whether measuring certain proteins in the blood (p-tau217 and neurofilament light) can help doctors diagnose Alzheimer's disease more quickly and confidently in people with memory problems. About 550 participants visiting a memory clinic will have their blood …

This study tests a new radioactive tracer called 18F-mFBG to see if it can detect nerve damage in the heart caused by Lewy body diseases like Parkinson's and Lewy body dementia. About 20 adults will get a PET scan after an injection of the tracer. The goal is to see if the scan c…

This early-stage study tests a new radioactive tracer called SST001 that lights up on PET scans. Researchers want to see if it is safe and can help tell the difference between multiple system atrophy (MSA) and Parkinson's disease. The study will include 30 healthy volunteers and …

This study tests whether a computer algorithm can reduce the amount of radiation or time needed for a special brain scan (amyloid PET) used to diagnose Alzheimer's disease. Researchers will compare standard scans with simulated lower-dose scans processed by the algorithm. If it w…

This study is testing whether a blood test that measures specific proteins (pTau217) can help primary care doctors diagnose Alzheimer's disease in people with memory concerns. Researchers will compare the test's accuracy against standard evaluations and track how it changes docto…

This study tests whether a tablet-based eye-tracking app (eVOG) can detect subtle eye movement problems in people with brain MRI abnormalities (white matter lesions). The goal is to see if these eye movement patterns can help diagnose multiple sclerosis or related conditions. Res…

This early-phase study tests a new radioactive tracer called [¹⁸F]MODAG-009 to see if it can safely highlight abnormal protein clumps in the brains of people with Parkinson's disease or multiple system atrophy (MSA). About 13 participants, including healthy volunteers, will recei…

This study tests a new radioactive tracer called 18F-Fluselenamyl for PET scans to safely detect amyloid plaques in the brain, a hallmark of Alzheimer's disease. Researchers will compare it to an existing tracer in 60 healthy volunteers and people with mild cognitive impairment o…

This study tests whether smartphone usage data can help tell the difference between normal memory complaints, mild cognitive decline, and Alzheimer's disease. Researchers will collect data from 90 participants' phones over three months. If it works, it could offer a simple, low-c…

This study explores whether a simple test of naming and identifying famous landmarks can tell apart healthy older adults from those with Alzheimer's disease. Researchers will compare the performance of 220 participants (half with Alzheimer's, half without) on this monument-based …

This study tests a special PET scan using [18F]PI-2620 to see if it can accurately detect tau tangles in the brains of people with Alzheimer's disease. About 200 adults aged 50 and older with a short life expectancy will get the scan. After they pass away, researchers will compar…

This early-stage study tests a radioactive tracer called [18F]Flortaucipir, used during a PET scan to detect tau protein tangles in the brain—a hallmark of Alzheimer's disease. Researchers will enroll 18 Chinese adults aged 50-85 with normal cognition, mild cognitive impairment, …

This study is testing whether blood tests can help screen for Alzheimer's disease in older adults during routine check-ups. Researchers will enroll 3,000 people aged 60-80 from communities and clinics. Participants will give blood samples, and those with abnormal results will tak…

This study is working on a new blood test for pregnant women that can check for serious genetic conditions like cystic fibrosis, spinal muscular atrophy, and sickle cell disease. Researchers will collect blood samples from 4,000 pregnant women who are at higher risk of passing on…

This study is testing a new, non-invasive way to detect Alzheimer's disease by looking for specific proteins (amyloid and tau) in stool samples. The goal is to see if these proteins can serve as early warning signs, potentially allowing for earlier diagnosis and treatment. Resear…

This study tests whether taking the sleep medication suvorexant (Belsomra) nightly for two years can slow the buildup of amyloid plaques in the brain, a hallmark of Alzheimer's disease. Researchers will enroll 200 healthy adults aged 65 and older with no signs of dementia. The go…

This phase 3 trial tests whether acoramidis can prevent or delay transthyretin amyloidosis (ATTR) in 587 adults who carry a faulty gene but have no symptoms yet. ATTR causes sticky plaques to build up in the heart and nerves, leading to heart failure and nerve damage. Acoramidis …

This study tests whether people with multiple sclerosis can learn to prevent falls by practicing on a treadmill that unexpectedly slips or trips. 64 participants aged 45 and older will be split into two groups: one gets the slip-and-trip training, the other just walks on the trea…

This study tests whether a device that flashes light and plays sound at 40Hz can prevent Alzheimer's disease in people at risk. 200 adults aged 55-90 with a family history of Alzheimer's will use the device at home for 60 minutes daily over 12 months. Researchers will measure cha…

This study is testing whether the Shingrix vaccine, already used to prevent shingles, can also lower the risk of dementia in adults aged 76 and older. Over 33,000 participants in Finland will receive either the vaccine or a placebo. Researchers will track new dementia diagnoses o…

This study explores whether mindfulness training can help prevent cognitive decline in Latino adults aged 65 and older, a group at higher risk for Alzheimer's disease. Researchers will measure brain activity and thinking skills in 60 participants before and after mindfulness prac…

This study tests a smartphone app designed to help people who use wheelchairs or scooters prevent and manage falls. Researchers will compare the app to standard fall prevention information in 120 adults with spinal cord injury or multiple sclerosis. The goal is to see which appro…

This study tests a brief problem-solving therapy to prevent suicide in adults aged 50 and older who have suicidal thoughts. The therapy is delivered in three formats: face-to-face, by phone, or via a smartphone app. 212 participants will be randomly assigned to one of these forma…

This study tests whether adding music-like sounds (sonification) to standard walking rehabilitation can improve gait, balance, and quality of life. 120 adults with Parkinson's disease, stroke, or multiple sclerosis will be randomly assigned to standard rehab or rehab with sonific…

This study tests whether spermidine, a natural substance found in foods like wheat germ, can improve sleep quality and memory in older adults with mild cognitive impairment (MCI), a condition that raises dementia risk. 76 participants aged 55-70 will take spermidine or a placebo …

This study tests a medicated skin patch (dexmedetomidine) to see if it can reduce agitation in people with Alzheimer's dementia. About 150 adults living in care facilities will receive either the patch or a placebo for 96 hours. The goal is to measure changes in agitated behavior…

This study tests whether exercise paired with simple mental tasks (like counting backwards) can improve walking, balance, and thinking in people with multiple sclerosis. Forty adults with MS will do supervised workouts twice a week for 8 weeks. The goal is to find better rehab st…

This study is testing the long-term safety of a combination of two drugs, KarXT and KarX-EC, for treating agitation in people with Alzheimer's disease. It is an open-label extension, meaning everyone knows they are getting the treatment. The study enrolls 600 participants who hav…

This study tests whether a virtual reality training program can help people with cerebellar ataxia improve their reaching movements. Participants will use an Oculus Rift headset to practice reaching to virtual targets over several weeks. The goal is to see if this type of trainin…

This phase 3 trial tests whether a combination of two drugs, KarXT and KarX-EC, can safely reduce agitation in people with Alzheimer's disease. About 352 adults will receive either the drug combo or a placebo for 14 weeks. The main goal is to see if agitation symptoms improve, as…

This study tests whether a non-invasive brain stimulation technique called HD-tDCS can improve visual and thinking abilities in people with posterior cortical atrophy (PCA), a rare condition often linked to Alzheimer's. Fifty participants will receive either real or sham stimulat…

This study tests whether the experimental drug ACP-204 can reduce psychosis symptoms like hallucinations and delusions in people with Lewy body dementia. About 180 adults aged 55 to 85 will take either ACP-204 or a placebo daily for 6 weeks. The goal is to see if the drug safely …

This Phase 3 trial tests whether the drug combination KarXT + KarX-EC can safely reduce psychosis symptoms (like hallucinations and delusions) in people with Alzheimer's disease. About 325 participants aged 55-90 will receive either the drug or a placebo. The study is currently r…

This study tests whether combining home-based brain stimulation (tDCS) with virtual speech therapy can improve communication in adults with primary progressive aphasia, a language disorder often caused by Alzheimer's disease. Eighty participants will receive either active or plac…

This study tests whether a safe, non-invasive brain stimulation technique called transcranial magnetic stimulation (TMS) can improve working memory in people with dementia. The stimulation is timed to each person's brain waves, measured by EEG, to help brain regions communicate b…

This study tests whether a personalized form of transcranial magnetic stimulation (TMS) can improve motor and non-motor symptoms in people with Parkinson's disease, multiple system atrophy, or progressive supranuclear palsy. Fifty participants will receive 10 days of targeted TMS…

This study tests whether a noninvasive brain stimulation technique called tDCS can reduce depression in people with multiple sclerosis. Participants use a headband-like device at home for 30 minutes a day over 30 days, while listening to mindfulness meditation. Half receive real …

This study is testing if a non-invasive brain stimulation method called HD-tDCS can help people with ALS. The goal is to see if it can improve muscle control and breathing by calming overactive brain cells. The study will involve 80 adults with ALS and will measure changes in bra…

This study tests a head-mounted far-infrared therapy device in 40 people with mild-to-moderate Alzheimer's disease. The device is placed on specific points on the head and delivers gentle heat. Researchers will check if it is safe and whether it helps improve cognitive function, …

This Phase 3 trial is testing whether a combination of two drugs, KarXT and KarX-EC, can improve cognitive impairment in people with mild to moderate Alzheimer's disease. About 586 participants will receive either the drug combo or a placebo. The study measures changes in memory,…

This study tests whether daridorexant, a sleep medication, can improve sleep in people with mild cognitive impairment or mild-to-moderate Alzheimer's disease who also have insomnia. Sixty-two participants will receive either the drug or a placebo for one month, and their sleep wi…

This phase 3 trial tests whether a combination of two drugs, KarXT and KarX-EC, can safely reduce agitation in people with Alzheimer's disease. About 352 adults with Alzheimer's-related agitation will receive either the drug combo or a placebo for 14 weeks. The main goal is to se…

This study tests whether repetitive transcranial magnetic stimulation (rTMS), a non-invasive procedure using magnetic pulses, can improve short-term memory in people with early Alzheimer's disease. Forty participants will receive either real or sham rTMS over four weeks, then be …

This study explores whether rhythmic auditory stimulation (like a metronome beat) can improve walking and brain function in people with Alzheimer's disease or mild cognitive impairment. Participants will walk while listening to rhythmic sounds, and researchers will measure change…

This early-phase study tests a 4-week training program that uses mixed reality to guide precise movements, like stacking virtual objects. The goal is to see if this can improve walking speed, balance, and thinking in people with multiple sclerosis. Thirty adults with MS will part…

This study tests a behavioral sleep program called Care2Sleep for people with Alzheimer's disease and their caregivers. The program includes sleep hygiene, activity, and light exposure. Researchers will compare it to a sleep education group to see if it improves sleep, health, an…

This study tests whether mild electrical or sensory stimulation can improve short-term memory for words in people with primary progressive aphasia (PPA), a condition that slowly damages language areas of the brain. Twenty participants will receive real or fake stimulation while d…

This Phase 3 trial tests whether the drug KarXT can safely reduce psychosis (hallucinations and delusions) in people with Alzheimer's disease. About 500 participants aged 55 to 90 with mild to severe Alzheimer's and moderate to severe psychosis will receive either KarXT or a plac…

This study tests if shining a special light on the head (transcranial photobiomodulation) can improve memory and thinking in people with mild cognitive impairment. Forty participants will receive either real or fake light sessions for 12 weeks. Researchers will measure brain acti…

This study tests whether custom 3D-printed cutlery handles can help people with neurodegenerative diseases eat more independently. 75 patients in rehabilitation care will try handles in different sizes, designed to fit their grip. Researchers will measure changes in eating abilit…

This study tests whether a mobile app called Tools for Coping with Cancer can help people with a history of cancer reduce distress and improve mood and quality of life. About 50 adults who have had cancer will use the app at home for 8 weeks and fill out questionnaires about thei…

This study tests a speech therapy program for bilingual Spanish-English or Spanish-Catalan speakers with primary progressive aphasia, a condition that slowly damages language abilities. Sixty participants will receive personalized script training via video sessions, while 30 othe…

This study tests a non-invasive brain stimulation technique called temporal interference stimulation (TIS) to see if it can improve cognitive function in people with mild cognitive impairment or early Alzheimer's disease. Sixty participants will receive either real TIS or a sham …

This study tests whether cognitive behavioral therapy for insomnia (CBT-I) can improve sleep and reduce fatigue in people with multiple sclerosis. About 70 adults with MS and insomnia will receive CBT-I or an active control. The goal is to see if this talk therapy approach can ea…

This study tests if pairing a gentle, non-invasive brain stimulation (tDCS) with personalized physical therapy can help people with cerebellar damage (from stroke, tumor, or degeneration) improve movement and daily function. About 30 adults aged 18-75 will participate. The goal i…

This study checks if a treatment called transcranial pulse wave stimulation (TPS) is safe for people with Alzheimer's disease. About 100 adults aged 18 to 85 will receive TPS sessions, and researchers will track any side effects and changes in memory and thinking. The goal is to …

This early study tests a virtual reality rehabilitation device for children with spinal muscular atrophy (SMA), a genetic condition that causes progressive muscle weakness. The device uses games, muscle sensors, and a grip-strength ball to make home exercises more engaging. Resea…

This phase 3 trial tests whether the drug KarXT can safely reduce psychosis (hallucinations and delusions) in people with mild to severe Alzheimer's disease. About 406 participants aged 55 to 90 will receive either KarXT or a placebo. The study aims to see if the drug improves sy…

This study tests an educational support group program for people with progressive aphasia (a language disorder caused by Alzheimer's or other dementias) and their carepartners. The program includes group education, support sessions, and communication skills training. Researchers …

This study explores whether group drumming or music listening can improve pain, stress, and brain function in people with early Alzheimer's, mild dementia, or mild cognitive impairment, as well as their caregivers. Over 8 weeks, 60 participants will attend weekly sessions while r…

This study tests a new drug called EI-1071 in 15 people with mild to severe Alzheimer's disease. The main goal is to see if the drug is safe and tolerable over 4 weeks. Researchers will also check if it reduces brain inflammation using special brain scans. Participants must have …

This study tests the safety and tolerability of the drug Zunveyl in 150 adults aged 50 and older with mild to moderate Alzheimer's disease. Over 12 weeks, researchers will monitor side effects and whether the drug helps reduce neuropsychiatric symptoms like agitation or mood chan…

This study tests an experimental oral drug, BMS-986368, for treating muscle stiffness (spasticity) in people with multiple sclerosis. About 200 participants will receive one of three doses of the drug or a placebo. The goal is to see if the drug safely reduces muscle tightness an…

This study tests if ranolazine, a heart medication, can safely reduce muscle cramps and improve quality of life in people with ALS. About 72 adults with ALS who have frequent cramps will receive either the drug or a placebo for 28 weeks. The main goals are to check safety and see…

This study tests whether solriamfetol (Sunosi), a drug used for sleepiness, can reduce fatigue in people with multiple sclerosis who also have excessive daytime sleepiness. About 46 participants will receive either the drug or a placebo for four weeks, then switch after a washout…

This study tests two experimental drugs, EXV-802 and EXV-801, to see if they can safely reduce agitation in people with Alzheimer's dementia. About 300 participants aged 55-90 with moderate to severe agitation will receive either the drug or a placebo twice daily for 6 weeks. The…

This study looks at whether two different exercise programs can help reduce depression in people with multiple sclerosis (MS) who also have major depressive disorder. Researchers will enroll 146 adults aged 18 to 64. One group will do a structured exercise program, while the othe…

This study tests whether a single injection of RE104 can reduce symptoms of depression or mixed depression and anxiety in people with adjustment disorder caused by a serious medical illness like cancer, ALS, multiple sclerosis, Parkinson's disease, or idiopathic pulmonary fibrosi…

This study tests whether a non-invasive brain-computer interface combined with 40Hz audio-visual stimulation can improve cognitive function in people with Alzheimer's disease. 90 participants will be randomly assigned to receive either fixed 40Hz stimulation, personalized closed-…

This study tests two types of speech therapy for adults with mild-to-moderate primary progressive aphasia, a condition that slowly impairs language. Researchers will compare the therapies in 200 participants to see which better improves communication and reduces caregiver burden.…

This study tests whether 8 weeks of mindfulness classes, taken together by people with Parkinson's and their family caregivers, can reduce negative emotions like stress, anxiety, and depression. About 200 Chinese patient-caregiver pairs will either take the classes or continue us…

This study tests an experimental oral medication (BMS-986368) to reduce agitation in people with Alzheimer's disease. About 120 participants will receive either a low dose, high dose, or placebo. The main goal is to see if the drug safely decreases agitated behaviors, such as pac…

This study tests whether silodosin, a drug typically used for enlarged prostate, can help women with multiple sclerosis who have bothersome urinary symptoms. Sixty female participants will take either silodosin or a placebo daily for 8 weeks. Researchers will use symptom question…

This study is testing whether a special flickering light therapy can improve memory and sleep in people with mild cognitive impairment or early Alzheimer's disease. About 120 participants will be randomly assigned to one of four light conditions and use the light at home for two …

This study tests whether a one-week smartphone training program can help unpaid caregivers of people with Alzheimer's disease better manage their emotions. Participants will be randomly assigned to learn one of two emotion-regulation techniques (distancing or reinterpretation) or…

This study tests whether dry needling—a treatment using thin needles to target tight muscles—can reduce chronic lower-limb pain in people with multiple sclerosis. Twenty-four participants will receive either real or sham dry needling over six sessions. Researchers also hope to se…

This small pilot study is testing whether a single infusion of human mesenchymal stem cells can help control agitation, aggression, and other behavioral symptoms in people with moderate to severe Alzheimer's disease. The study involves 8 adults aged 55-90 who are already taking a…

This study tests whether balance rehabilitation that changes how patients see (closing eyes, using a mask, or projecting moving dots) can improve walking stability better than standard rehab with eyes open. It includes 40 adults with chronic nerve damage who have trouble with bal…

This study tests whether a single 30-minute session of transcutaneous electrical nerve stimulation (TENS) on the face can reduce jaw and facial pain, improve jaw movement, and make chewing easier for people with ALS or PLS. Ten participants will receive the treatment during one c…

This study tests whether restricting eating to a 10-hour daytime window (fasting 14 hours overnight) can reduce sleep problems and cognitive decline in people with mild cognitive impairment or early-to-moderate Alzheimer's disease. Sixty older adults will try the diet for 3 or 6 …

This study tests whether an app called Genus, which provides videos, exercises, and quizzes, can help people with knee osteoarthritis learn more about their condition and feel more confident in treatment decisions. About 204 adults over 50 who are waiting for a specialist appoint…

This Phase 2 study tests an experimental drug, ML-007C-MA, to see if it can safely reduce hallucinations and delusions in people with Alzheimer's disease. About 300 participants aged 55 to 90 will receive either the drug or a placebo. The main goal is to measure changes in psycho…

This study tests whether IGC-AD1, a THC-based oral medication, can safely reduce agitation in people with mild to severe Alzheimer's dementia. About 164 participants will receive either the drug or a placebo twice daily for several weeks. Researchers will measure changes in agita…

This study tests whether a non-invasive nerve stimulation device placed on the ankle can reduce bladder symptoms like urgency and frequent urination in people with multiple sclerosis. 72 participants will be randomly assigned to receive either real or sham stimulation over severa…

This study is testing a culturally adapted online education program called Tele-Savvy for Latino caregivers of people with Alzheimer's or related dementias. The program includes weekly video group sessions and short instructional videos over seven weeks. Researchers want to see i…

This study is testing an app called PancreasPlus for people with pancreatic cancer. The app helps patients track symptoms, get information, and communicate with their care team from home. Researchers want to see if using the app improves quality of life, reduces anxiety, and cuts…

This study tests whether a virtual, home-based exercise program can reduce depression and anxiety in family caregivers of people with Alzheimer's disease. Twenty-five caregivers will be randomly assigned to either the exercise program or a wait-list group. The program includes we…

This pilot study tests a mechanical in-exsufflator (MIE) device that helps ALS patients cough more effectively by pushing air in and then pulling it out. The goal is to see if daily use for four weeks can maintain or improve lung function. The study will enroll 36 adults with ALS…

This study tests a powered leg brace called the Nomad in 36 people who have trouble walking due to conditions like stroke, multiple sclerosis, or spinal cord injury. Participants will use the brace at home for three months to see if it improves their walking speed, balance, and q…

This study tests a five-week tongue exercise program for 20 people with ALS to see if it can help with swallowing and speech. Participants press their tongue against a device at home five days a week, with weekly check-ins via telehealth. Researchers will measure tongue strength …

This study tests a new device that uses focused ultrasound waves on the brain to see if it can safely improve movement problems in people with Parkinson's disease. About 60 adults with Parkinson's will receive either real or fake (sham) ultrasound treatments. Researchers will mea…

This study tests an experimental drug called ONO-2020 to see if it can safely reduce agitation in people with Alzheimer's disease dementia. About 90 participants in Japan will receive either the drug or a placebo daily for several weeks. Researchers will measure changes in agitat…

This study tests whether psilocybin (the active ingredient in magic mushrooms) can safely reduce depression in adults with COPD, ALS, MS, or atypical Parkinson disease who have at least 6 months to live. Participants receive either two moderate-to-high doses (15mg then 25mg) or t…

This pilot study tests a combination of two non-invasive brain stimulation methods (iTBS and tDCS) in 20 veterans with mild-to-moderate Alzheimer's disease who also have mood swings, apathy, or agitation. Participants will receive one week of in-clinic iTBS sessions followed by f…

This study explores whether intensive singing lessons can improve thinking, memory, and mood in people with early-stage Alzheimer's. Over 5 months, participants will take twice-weekly singing lessons with a personal teacher, then switch to once-a-month sessions. Researchers will …

This study tests whether a special light that flickers 40 times per second can help people with mild to moderate Alzheimer's disease. For 6 months, 62 participants will use the light device at home for 1 hour each day. Researchers will measure changes in brain activity, memory, a…

This study tests whether a home-based program combining computer brain games with physical exercises can improve thinking and walking in people with multiple sclerosis (MS). Ninety adults with MS will be randomly assigned to different training groups. The goal is to see if the co…

This study looks at whether a simple device that makes you breathe in a little extra carbon dioxide (CO2) can help raise blood pressure in people with a condition called neurogenic orthostatic hypotension (nOH). People with nOH get dizzy or even faint when they stand up because t…

This study tests whether using mixed reality (a blend of real and virtual environments) can improve hand strength, coordination, and quality of life in people with multiple sclerosis. Thirty participants will either receive standard physiotherapy or standard therapy plus mixed re…

This study tests a new drug called CST-3056 in 12 adults with neurogenic orthostatic hypotension (a sharp drop in blood pressure when standing) caused by Parkinson's disease or pure autonomic failure. The goal is to see if the drug can improve blood pressure and reduce symptoms l…

This study tests whether personalized virtual music therapy can boost memory and mood in people with mild cognitive impairment or early Alzheimer's disease. Sixty participants will receive two 30-minute online music therapy sessions each week for 8 weeks, led by a certified thera…

This pilot study tests whether switching from ocrelizumab to ublituximab can reduce or delay the return of MS symptoms that some patients experience before their next scheduled infusion. Researchers will enroll 50 adults with relapsing MS who have been on ocrelizumab for at least…

This Phase II trial tests whether a safe, non-invasive brain stimulation technique called tDCS, combined with language therapy, can improve word-finding in people with primary progressive aphasia (PPA). The study enrolls 180 adults aged 50–90 with certain types of PPA. Participan…

This study is testing whether computerized brain training (BrainHQ) and Tai Chi-Qi Gong can improve memory, thinking, and mood in people with early-onset Alzheimer's disease. Sixty participants aged 40-64 will be assigned to either the training program or an active control group.…

This study tests a non-invasive brain stimulation method called temporal interference stimulation (TIS) to see if it can improve motor and speech problems in people with Parkinson's disease or secondary Parkinson's syndrome. Sixty participants will receive either real TIS or a sh…

This study tests whether doing thinking tasks (like counting backwards or matching colors) at the same time as physical exercises can improve walking, balance, and memory in teens with pediatric-onset multiple sclerosis. Twenty-two participants aged 12–18 will be randomly assigne…

This study tests a new 8-week program that combines motor imagery (mentally practicing movements) with vestibular rehabilitation (exercises for balance and dizziness) in 30 people with relapsing-remitting multiple sclerosis. The goal is to see if this combination improves balance…

This study tests whether a device that sends mild electrical currents to the brain (hi-tACS) can improve sleep in people with neuroimmune diseases like multiple sclerosis who also have insomnia. Eighty participants will receive 20 sessions of the stimulation or a sham treatment. …

This study tests a web-based program called NiteCAPP designed to improve sleep in people caring for a loved one with dementia, especially those living in rural areas. One hundred caregiver-patient pairs will use the program for 4 weekly sessions plus follow-up boosters. Researche…

This study tests whether exercising to beat-accented music helps older adults (65+) with memory concerns stay active and improve thinking skills. Eighty participants will be randomly assigned to a 6-month exercise program with or without special music. The goal is to see if music…

This study tests whether adding electroconvulsive therapy (ECT) to usual care can safely reduce severe agitation in people with moderate to severe dementia, including Alzheimer's and other types. Fifty participants will receive ECT sessions with anesthesia, and researchers will m…

This study examines whether the drug omaveloxolone can ease swallowing difficulties in people with Friedreich's ataxia, a rare nerve disease. About 40 French patients who have taken the drug for at least six months will fill out a swallowing questionnaire. The goal is to see if t…

This early-stage trial tests whether low-intensity focused ultrasound (LIFU) can safely improve motor symptoms in 24 adults with Huntington's disease. Participants receive ultrasound pulses to a brain region involved in movement control. The study focuses on safety and finding th…

This study investigates how fluid drains from the brain to lymph nodes in the neck, a connection that may be important for clearing waste linked to Alzheimer's disease. Researchers will inject a fluorescent dye into the meningeal space of recently deceased organ donors and track …

This study explores whether a small accelerometer worn on the thigh can objectively measure how well treatments work for neurogenic orthostatic hypotension—a condition causing dizziness and fainting upon standing. Participants wear the device for one week on placebo and one week …

This study uses special PET scans to measure inflammation in the brains of people with Alzheimer's, Parkinson's, ALS, and other neurodegenerative diseases. Researchers will compare these scans to those from healthy volunteers to see if inflammation levels differ. The goal is to d…

This long-term observational study uses MRI scans to track how multiple sclerosis (MS) changes over time in up to 3750 people. Researchers will compare brain images and immune system markers in untreated patients, those on approved therapies, and healthy volunteers. The goal is t…

This study aims to learn more about rare inherited disorders that affect the brain, spinal cord, muscles, and nerves. Researchers will collect medical history, perform exams, and run genetic tests on up to 3,500 participants. No new treatments are tested; the goal is to better un…

This study uses yearly PET scans to track amyloid protein buildup in the brains of 400 adults aged 55 and older over 5 years. Participants are already part of the Baltimore Longitudinal Study of Aging. The goal is to see how these brain changes relate to memory loss and other thi…

This study investigates whether the bacteria causing Lyme disease can survive antibiotic treatment and cause ongoing symptoms. Researchers will follow 700 participants, including those with chronic Lyme disease, recovered individuals, and healthy volunteers, using blood tests, sp…

This observational study is recruiting 2400 people with immune-related central nervous system diseases, such as multiple sclerosis, along with healthy volunteers for comparison. Researchers will use MRI scans, lumbar punctures, blood tests, and neurological exams to track disease…

This international observational study will follow 50,000 people with Alzheimer's disease or related dementias for many years. Researchers will collect real-world data from routine doctor visits to track how the disease progresses and how treatments are used and tolerated. The go…

This study tests a new radioactive tracer to see if it can measure brain inflammation in people with Alzheimer's disease or mild cognitive impairment. Researchers will compare scans from 90 volunteers (patients and healthy older adults) to understand how inflammation relates to m…

This study aims to enroll 50,000 adults aged 45 and older in France to test for a gene called APOE, which is linked to Alzheimer's risk. Participants provide a saliva sample at home and complete online questionnaires. The goal is to build a large registry of genetic and health da…

This study follows people with rare genetic disorders that cause harmful substances to build up in the body, leading to brain damage. Researchers will monitor up to 200 participants over time using exams, surveys, and lab tests. The goal is to better understand how these diseases…

This study aims to create a risk score that uses information from electronic medical records to predict the chance of developing dementia within 5, 9, or 13 years in older adults with depression. Researchers will analyze data from 44 participants aged 50 and older who have a depr…

This study screens 360 adults with neurodegenerative disorders like ALS, frontotemporal dementia, and progressive supranuclear palsy. Researchers will use medical history, physical exams, memory tests, movement analysis, MRI scans, and other tests to find common features and diff…

This study enrolls 600 adults with Huntington disease to examine specific genetic markers (SNPs) linked to the disease. Participants provide a blood sample and answer questions about their health and medications. The goal is to better understand the genetics of Huntington disease…

This study gathers information from memory clinics across France to track how many people have Alzheimer's disease, how it progresses, and what factors affect diagnosis and care. Researchers will analyze anonymous medical records from over 500 centers to spot trends in health and…

This study examines whether a person's personality traits before they got sick are linked to the thinking and behavior problems seen in certain brain disorders. Researchers will ask caregivers about the patient's personality from the 10 years before the illness started. The goal …

This study looks at how differences in the NOTCH2NLC gene affect the symptoms and course of neuronal intranuclear inclusion disease (NIID), a rare inherited brain disorder. Researchers will follow 12 members of one family, including those with NIID, gene carriers without symptoms…

This study follows 2,800 unpaid caregivers of people with chronic conditions like diabetes or inherited disorders. Researchers will survey and interview caregivers over up to 5 years to track changes in their health, stress, and social support. The goal is to understand how careg…

This study is analyzing inflammatory markers in the blood and spinal fluid of 300 people who are being checked for multiple sclerosis (MS). The goal is to see if certain markers can help doctors tell MS apart from other autoimmune diseases that affect the brain and spinal cord. R…

This study follows 700 people with progressive multifocal leukoencephalopathy (PML), a rare brain infection caused by the JC virus. Researchers will collect blood, spinal fluid, and brain scans over time to understand how the disease progresses. No treatment is given; the goal is…

This study follows 650 people aged 8 to 99 with androgen insensitivity syndrome (AIS) to better understand their long-term health. Researchers will track hormones, bone density, heart health, metabolism, and tumor risk through regular check-ups and scans. No treatments are being …

This study screens up to 5,000 healthy volunteers and people at risk for psychiatric or neurodevelopmental disorders like autism. Participants undergo interviews, cognitive tests, and other evaluations to see if they qualify for future research studies at NIH. The goal is to buil…

This study is looking for biological clues in the blood that explain why many people with ALS lose weight. Researchers will follow 1,000 patients in France and Germany, collecting blood samples and questionnaires alongside standard care. The goal is to find markers that could lea…

This study is for people diagnosed with ALS, MND, or PLS. Participants fill out an online survey once a month about their physical function, diet, supplements, medications, and mental outlook. The goal is to see which therapies and behaviors are linked to better outcomes. No new …

This study is observing 40 adults with multiple sclerosis to see how clinical tests of balance and walking relate to detailed motion-capture measurements. Participants will attend one session where they walk on force plates and perform balance tasks while cameras track their move…

This study aims to create a smartphone system that sends personalized pain management tips to adults with multiple sclerosis or spinal cord injury who have chronic pain. Researchers will interview participants to understand their preferences for the content and timing of these no…

This study is testing a new, painless device called electrical impedance myography (EIM) to measure muscle health. Researchers will use it on healthy volunteers and people with neuromuscular diseases to see how well it works compared to standard tests like ultrasound and nerve st…

This study looks at how certain brain cells (cholinergic neurons) change with age in adults with Down syndrome, and how that relates to Alzheimer's disease risk. Researchers will use brain scans and EEGs to measure these changes in 30 adults aged 18-55 who do not have dementia. T…

This study tests a new, non-invasive MRI technique to detect early brain changes linked to Alzheimer's disease. Researchers will compare brain scans from 50 people with mild memory concerns to healthy volunteers. The goal is to find a simple, affordable way to identify those at r…

This study is testing whether monthly blood tests for a nerve damage marker (neurofilament light chain) can detect hidden disease activity in people with relapsing-remitting multiple sclerosis (MS) earlier than standard yearly MRI scans. The goal is to reduce the need for gadolin…

This study follows 600 adults who are genetically at risk for ALS due to family history. Over three years, researchers collect blood samples, speech recordings, and health data to track early signs of the disease. The goal is to build a rich database that scientists can use to be…

This study follows 100 women with neuroimmune diseases (like multiple sclerosis or myasthenia gravis) through pregnancy and up to five years after. Researchers will track disease activity, pregnancy complications, and baby health to learn how these conditions affect fertility and…

This study looks at early changes in mitochondria (the energy centers of cells) and metabolic markers in blood cells of people with Alzheimer's or related dementias. Researchers will compare these measures between those with and without Alzheimer's to find clues about how the dis…

This study is gathering medical information, blood samples, and speech recordings from 2,000 people with ALS and healthy volunteers over two years. The goal is to create a shared resource that scientists can use to better understand ALS and develop new treatments. Participants ca…

This registry study will follow 2000 people with relapsing multiple sclerosis who are prescribed BRIUMVI (ublituximab-xiiy) in real-world settings. Researchers aim to track safety, effectiveness (like relapse rates), and the overall treatment experience. Participants must not hav…

This study looks at how much of the multiple sclerosis drug BRIUMVI gets into breast milk. About 16 breastfeeding women with relapsing MS will provide milk samples after their regular treatment. The goal is to understand drug exposure for nursing infants, not to test a new treatm…

This registry study follows pregnant women with multiple sclerosis (MS) who have taken BRIUMVI, comparing them to those who haven't taken the drug. The goal is to see if BRIUMVI increases the risk of major birth defects. Researchers will enroll about 728 participants across two g…

This study examines how spinal posture and movement relate to balance in 30 adults with relapsing-remitting multiple sclerosis. Researchers will measure spinal angles and mobility, then compare them with balance tests. The goal is to identify links that could inform future rehabi…

This study follows 60 people with ALS to see how swallowing problems change over time and how they affect quality of life. Researchers also want to understand patients' feelings about getting a feeding tube (PEG). The goal is to learn more, not to test a new treatment.

This observational study will enroll up to one million adults to understand how health, environment, and lifestyle affect aging and disease. Researchers will link participants' clinical data with information from public records, such as pollution and social factors, to create a d…

This early-stage study is testing an experimental drug called LY3439539 in 30 people with mild-to-moderate Alzheimer's disease. The main goal is to see if the drug changes certain proteins in the spinal fluid that are linked to Alzheimer's. Participants will receive the drug thro…

This observational study follows 170 people with multiple sclerosis, neuromyelitis optica, and similar conditions, plus healthy volunteers, for up to 6 years. Researchers use MRI scans, blood tests, and spinal fluid analysis to monitor brain lesions and understand how the disease…

This study gathers information from the medical records of 1,200 people with ALS and similar conditions. Researchers will use this data to better understand the disease and improve future studies. No experimental treatments are given—the goal is simply to learn from real-world pa…

The CLUE study is a research project that follows 1,000 people with neuroinflammatory diseases like multiple sclerosis and neuromyelitis optica. Participants undergo detailed MRI and PET scans at the start and after one year to see how their brain, spinal cord, and optic nerves c…

This study is observing tiny energy-producing parts of cells, called mitochondria, in the spinal fluid of people who have had a stroke or have Alzheimer's disease. Researchers want to see if these markers relate to how well patients recover after a stroke. The study does not give…

This observational study, led by the Michael J. Fox Foundation, aims to understand how Parkinson's disease progresses over time. It will follow 4,500 people, including those with Parkinson's, those at risk, and healthy volunteers, collecting clinical, imaging, and genetic data. T…

This study follows 214 people in China with multiple system atrophy, a rare and fast-worsening brain disease that affects movement and automatic body functions. Researchers will track symptoms over time to learn how the disease progresses and what factors influence it. The goal i…

This study collects a small sample of tissue from inside the nose to learn how the sense of smell changes in people with Alzheimer's. Researchers will compare samples from healthy volunteers and those with early or mild Alzheimer's. The goal is to understand the biology behind sm…

This study looks at whether special breathing exercises can help the brains of people with multiple sclerosis or cancer, as well as their caregivers. Researchers will use MRI scans to see how breathing affects oxygen flow in the brain. The goal is to understand the connection bet…

This study follows 800 adults with synucleinopathies—diseases like Parkinson's, Lewy body dementia, and multiple system atrophy—to learn how they develop and change over time. Researchers will track symptoms, biological markers, and early signs like dizziness on standing or dream…

This study will follow 1,000,000 adults aged 18 and older for the rest of their lives. Researchers will collect health measurements and track who develops diseases, becomes frail, or dies. The goal is to find which tests best predict how well people age, so doctors can one day of…

This study follows 160 people with relapsing multiple sclerosis in Greece who are already taking ofatumumab (Kesimpta®) as part of their routine care. Researchers will track how many patients have no signs of disease activity—like relapses, new brain lesions, or worsening disabil…

This study looks at whether smartwatches can help monitor chronic inflammatory demyelinating polyneuropathy (CIDP), a rare nerve disease that causes weakness and numbness. 35 adults with CIDP who use subcutaneous immunoglobulin therapy at home will wear a smartwatch for 12 months…

This study looks at how depression and very early (preclinical) Alzheimer's disease affect driving habits in adults aged 65 and older who still drive regularly. Participants will have their driving tracked with a GPS device and undergo brain scans to measure Alzheimer-related pro…

This study aims to collect DNA samples and detailed eye exam data from 1,000 people with rare inherited eye diseases like aniridia, Best disease, and albinism. Participants provide a saliva or blood sample and share their eye health records. The goal is to expand a research repos…

This study tests a new type of MRI that looks at energy use in the brain to see if it can predict how well multiple sclerosis (MS) patients will respond to a common therapy. Researchers will scan 40 adults with relapsing-remitting MS before and after they start treatment. The goa…

This study uses a special PET scan to look at tau protein buildup in the brain and see if it relates to memory and thinking problems. Researchers will study 900 adults, some with normal memory and some with mild dementia. The goal is to better understand Alzheimer's disease, not …

This study follows 65 people with Friedreich ataxia who also have a thickened heart muscle (cardiomyopathy). Researchers will measure changes in heart structure over time using imaging. The goal is to better understand how heart disease progresses in this condition, which could h…

This study follows 20 adults with multiple sclerosis who are already scheduled for a stem cell transplant. Researchers will measure levels of an immune-suppressing drug called ATLG and track how the immune system rebuilds itself afterward. The goal is to learn more about immune r…

This study uses brain scans (PET and MRI) to find early signs of Alzheimer's disease in 650 adults with normal cognition or early-stage symptoms. Participants receive special tracers that highlight amyloid and tau proteins in the brain. The goal is to understand how these biomark…

This study tests a new radioactive tracer called [11C]-CS1P1 to see if it can detect inflammation in the brains of people with Alzheimer's disease. Researchers will compare brain scans from 80 older adults—some healthy and some with memory problems—to see if the tracer lights up …

This study looks at how the FDA-approved drug edaravone (Radicava) affects people with different forms of ALS. Researchers will collect blood, urine, and spinal fluid samples from 160 participants to measure markers of oxidative stress. The goal is to identify which ALS patients …

This pilot study tests whether a radioactive tracer called 89Zr-Df-crefmirlimab can help PET scans detect certain immune cells (CD8+ T cells) in the brain and spinal cord of people with multiple sclerosis (MS) or progressive multifocal leukoencephalopathy (PML). About 15 adults w…

This study is a large-scale screening program to find people who may be eligible for Roche's Alzheimer's drug trials. It involves a simple blood test and a memory assessment. Up to 13,000 participants with memory concerns will be evaluated. No experimental treatment is given in t…

This study follows 250 adults with multiple sclerosis (or similar conditions) for years, using yearly MRI scans and other tests to track brain and spinal cord changes. After a participant passes away, researchers examine donated brain and spinal cord tissue to see how the MRI fin…

The CROWN-I study is an observational research project involving 160 people with Alzheimer's disease or mild cognitive impairment. Participants will provide samples and undergo assessments over time to help researchers understand the molecular and genetic features that distinguis…

This study is testing a new radioactive tracer called [18F]MODAG-009 in 6 healthy adults. The goal is to see how the tracer moves through the body and how much radiation exposure it causes. Participants get one injection and then a full-body PET scan. This is an early-phase study…

This observational study is recruiting 600 participants to improve detection and understanding of dementia with Lewy bodies (DLB). Researchers will collect clinical data, brain scans, and spinal fluid samples from people with early symptoms like hallucinations or movement problem…

This large nationwide study in China will track nearly 10,000 people with Alzheimer's disease to measure the financial and emotional burden on patients and their caregivers. Researchers will collect data on medical expenses, care costs, and lost income. The goal is to fill gaps i…

This study looks at how stroke changes the way the brain handles walking while doing another task, like listening or navigating. Researchers will monitor brain activity in 50 stroke survivors as they walk on different paths and respond to sounds. The goal is to better understand …

This study is testing whether an advanced MRI technique called Quantitative Susceptibility Mapping (QSM) can better tell apart brain lesions caused by multiple sclerosis (MS) from those due to normal aging or small vessel disease. Researchers will scan 1,000 people aged 50-70 wit…

This observational study looks at how sleep quality influences cognitive flexibility, physical activity, body awareness, and reaction time in people with multiple sclerosis. Researchers will compare those with good and poor sleep using questionnaires, computer tests, and a wearab…

This study aims to learn more about Chediak-Higashi syndrome, a rare genetic disorder that causes light skin and hair, easy bruising, and frequent infections. Researchers will observe up to 60 patients over time, collecting clinical and genetic data to better understand the disea…

This study is not testing a new drug. Instead, it will observe 800 people with relapsing multiple sclerosis in Germany who are already taking approved injectable or oral medications. Researchers will track how long patients stick with their prescribed treatment over up to four ye…

This study uses a special PET scan to measure brain inflammation in people with fibromyalgia, chronic fatigue syndrome, multiple sclerosis, and healthy volunteers. Researchers want to see if those with pain and fatigue have higher levels of brain inflammation. The study does not …

This early-stage study tests a brain implant called BrainGate in just 3 people with severe paralysis or speech loss from conditions like ALS or spinal cord injury. The goal is to see if the device is safe and can let users control a computer cursor or other tools by thought alone…

This study looks back at 483 patients who had small rectal neuroendocrine tumors (less than 2 cm) removed using one of two endoscopic techniques: endoscopic submucosal dissection (ESD) or endoscopic partial muscle resection (EPMR). The goal is to compare how often each method lea…

This study uses a special PET scan to measure a harmful protein called tau in the brains of 160 people with Alzheimer's disease. Researchers want to see how tau buildup relates to a person's thinking abilities, race, and heart health risks. Participants are already part of a larg…

This study looks at why people with Alzheimer's disease may move more slowly. Researchers will use brain MRI scans and simple reaction time tests in 155 participants with mild cognitive impairment or early dementia. The goal is to link brain lesions to attention-related motor slo…

This study from Mayo Clinic looks at how multiple sclerosis (MS) affects the autonomic nervous system, which controls things like blood pressure, skin blood flow, and bladder health. Researchers will compare 13 people with MS to healthy volunteers using simple lab tests. The goal…

This study follows 842 people with multiple sclerosis who are starting a new under-the-skin injection of ocrelizumab. Researchers will ask participants how satisfied they are with the injection after 1, 6, and 12 months. The goal is to understand patient experience, not to test t…

This study looks at immune cells in the gut to understand how they might be linked to multiple sclerosis, Parkinson's disease, and REM sleep behavior disorder. Researchers will collect colon tissue samples from 100 adults during colonoscopy. The goal is to map these cells and the…

This study follows 20 people from families with a genetic risk for frontotemporal dementia (FTD), including those already diagnosed and those at risk. Over five years, researchers will track changes in health and brain function to better understand how the disease develops. The g…

This study looks at how body awareness (knowing where your body is in space), trunk (core) stability, and arm function are related in people with multiple sclerosis (MS). Researchers will measure these abilities in 50 adults with MS and compare them to healthy volunteers. The goa…

This study follows 200 people with Multiple System Atrophy (MSA) to see if receiving care from a team of specialists every four months improves their quality of life and eases the burden on their caregivers. Participants and their doctors will complete questionnaires about daily …

This study looks at whether the 'stickiness' or viscosity of the carotid artery wall differs between people with vascular dementia and those with Alzheimer's disease. Researchers will measure artery wall viscosity in 140 older adults using ultrasound and pressure sensors. The goa…

This registry collects information from people with inherited retinal diseases, like retinitis pigmentosa and Stargardt disease. Participants share their symptoms, family history, and genetic test results online. The goal is to help researchers understand these rare diseases and …

This study is building a large database of health information from 5,000 people with ALS and other motor neuron diseases. Participants share details like symptoms, test results, and disease progression during regular clinic visits. The de-identified data is then shared with resea…

This study aims to find genetic causes and risk factors for ALS by analyzing DNA from 1,200 people in Norway with probable or definite ALS. Researchers will look for known disease-causing mutations and search for new genes linked to the disease. The goal is to better understand w…

This study is testing whether a smartphone app can accurately measure how people walk, without needing special markers or equipment. Researchers will compare the app's measurements to a standard motion-capture system in 30 volunteers—some with neuromuscular diseases like SMA or m…

This study gives a single dose of kisspeptin, a natural hormone, to 40 people with and without Long COVID. Researchers will take frequent blood samples to measure how the brain's reproductive hormone system responds. The goal is to understand if Long COVID disrupts this system, w…

This study is creating a new computer-based cognitive assessment to help detect Alzheimer's disease in its earliest stages. Researchers are working with memory nurses and older adults to design the test and a training course for nurses. 120 older adults with memory concerns will …

This study enrolls adults with Down syndrome ages 25-55 into a ready-to-test group. Researchers will track memory, thinking, and brain changes over time to better understand how Alzheimer's disease develops in this population. The goal is to make future clinical trials faster and…

This study looks at whether special brain cells called tanycytes play a role in Alzheimer's disease and frontotemporal dementia. Researchers will measure hormone levels in blood and spinal fluid from 102 participants to see if these cells help control metabolism and hormone signa…

This study aims to find genes that increase the risk of developing Alzheimer's disease. Researchers are recruiting 10,000 people, including those with Alzheimer's and their family members, from all ethnic backgrounds. By analyzing DNA, they hope to discover new genetic clues that…

This study looks at whether changes in smell and taste contribute to poor nutrition in people with ALS. Researchers will measure food preferences in 60 adults with ALS using a computer test. The goal is to find new ways to improve diet and quality of life by personalizing food ad…

This 7-year study follows 3,400 adults who report no memory problems but may be at risk for Alzheimer's. Researchers will use a blood test measuring P-tau217, a protein linked to Alzheimer's, to see if higher levels predict faster cognitive decline. The goal is to better understa…

This study is trying to figure out what makes someone more likely to develop multiple sclerosis (MS). Researchers are looking at a mix of genetic, environmental, and immune factors in 5,000 people in the US, including relatives of MS patients and others at higher risk. The goal i…

This study looks at whether a new eye-tracking device can help doctors see how well multiple sclerosis (MS) treatment is working. About 224 Canadian adults with relapsing-remitting MS will use the device during routine care. The goal is to find out if eye movement changes can rep…

This study looks at whether new, quick tests that measure how fast people can move can help doctors diagnose brain diseases like Alzheimer's and predict recovery after a stroke. Researchers will test 129 adults aged 40-85 with stroke or memory problems. The goal is to see if thes…

This long-term study follows 700 adults who carry a rare genetic mutation that causes early-onset Alzheimer's. Researchers collect blood, spinal fluid, brain scans, and cognitive tests to find biomarkers that signal the disease before memory loss begins. The goal is to improve ea…

This study looks at how tired people with spinal muscular atrophy (SMA) feel during daily activities while taking the drug nusinersen. Researchers will use a new questionnaire called the SMA EFFORT to measure this fatigue. The goal is to better understand fatigue in SMA and see i…

This study follows up to 60 babies with spinal muscular atrophy (SMA) found at birth, plus 30 healthy babies, for up to 30 months. Researchers use wearable devices worn at home to track muscle development and find when movements start to differ from normal. The goal is to identif…

This early-phase study is testing the safety and how the body handles a new oral drug called AS-S603, which is being developed to treat Alzheimer's disease. The trial involves 88 healthy volunteers, including Korean and Caucasian adults and Korean elderly people. Participants wil…

This study looks at how multiple sclerosis (MS) affects hearing. Researchers will test hearing and analyze spinal fluid from 30 adults with MS to see if hearing problems are linked to inflammation in the body. The goal is to better understand MS, not to test a new treatment.

This study will explore whether sleep apnea makes multiple sclerosis worse. Researchers will collect sleep studies, MRIs, and lab results from 800 adults with MS to see if there is a link. The goal is to better understand how sleep problems might affect the brain and overall heal…

This study is a national registry for people with adrenoleukodystrophy (ALD), a rare genetic disorder. Researchers will collect medical records and survey data from up to 1,000 patients and their families over time to understand how the disease progresses. The goal is to find bet…

This study looks at 240 adults aged 40-60 to see if being overweight or obese in midlife is linked to early signs of Alzheimer's in the brain. Participants will have metabolic tests and brain scans (MRI and PET) to measure inflammation, brain shrinkage, and protein buildup. The g…

This study is for people with ALS and healthy volunteers. It uses brain and spine MRI scans and blood tests to find markers that show how the disease progresses. The goal is to develop better tools to measure ALS over time. About 90 participants will be followed for up to one yea…

This study looks at how people with mild multiple sclerosis adjust their walking when faced with obstacles or sudden changes, compared to healthy adults. Researchers will use motion sensors and brain activity monitors to measure these skills. The goal is to find better ways to de…

This study is testing a new memory test called MAI in 60 adults aged 70 and older. Half have memory disorders like Alzheimer's, and half do not. The goal is to see if the test can tell the difference between the two groups and help doctors detect memory problems earlier.

This study tests a digital tool called CGM ASSIST that combines a continuous glucose monitor with easy-to-read displays. The goal is to help people with Alzheimer's or dementia and diabetes, along with their caregivers, better understand blood sugar levels and make informed decis…

This study compares swallowing function in older adults with and without Alzheimer's disease. Researchers will also survey caregivers to understand the burden of swallowing issues. Participants will undergo tests of swallowing, coughing, and muscle strength. The goal is to learn …

This study looks at how difficult childhood experiences might impact the course of multiple sclerosis (MS). Researchers will work with 300 young adults with relapsing-remitting MS, focusing on Black, Hispanic, and low-income groups often left out of research. Participants will ha…

This study tests whether a non-invasive technique called repetitive Transcranial Magnetic Stimulation (rTMS) can improve memory and brain function in older adults with mild cognitive impairment or early Alzheimer's. Over 30 participants will receive both real and sham (placebo) s…

This study tests new methods to improve how dementia clinical trials are run. Researchers want to see if a combined score of thinking and daily function can better measure treatment effects. They will also check if blood proteins can predict who responds to the Alzheimer's drug d…

This study looks at how the brain plans and produces speech in people who stutter, those with primary progressive aphasia, and healthy speakers. Participants will practice saying made-up words with tricky sound combinations while researchers measure brain activity with MRI and tr…

This study aims to find early brain scan markers that can predict when multiple sclerosis (MS) will get worse. Researchers will use powerful MRI machines to look at brain chemistry and structure in 50 adults with MS. The goal is to identify signs of nerve damage before permanent …

This study is developing a standard test to measure how well assistive technologies (like eye trackers) and brain-computer interfaces help people with spinal cord injury or ALS use computers and phones. Researchers will test 60 participants, including healthy volunteers and peopl…

This study uses special PET scans to measure tau protein buildup in the brains of 332 people with Progressive Supranuclear Palsy (PSP), a rare brain disorder that affects movement and balance. Researchers want to see how tau levels change over time and relate to symptoms. Partici…

This study looks at how muscles grow and change in children with cerebral palsy (CP) by examining tiny samples from leg muscles. Researchers will compare these microscopic findings with muscle images and movement tests. The goal is to better understand why muscles in CP develop d…

This study is building a large database and biobank from 2200 people with chronic inflammatory diseases like lupus, multiple sclerosis, severe asthma, and psoriasis. Researchers will collect blood samples and track disease activity over time using standard medical scores. The goa…

This study is testing a mobile app called Wysa for Chronic Pain, designed to support people aged 45 and older who have chronic pain along with depression or anxiety. Researchers want to see if personalized in-app notifications can encourage people to use the app more often. Parti…

This study will test whether a special eye scan (OCT) can detect changes in the retina that show how well the MS drug ublituximab is working. Researchers will compare 15 people starting ublituximab with 15 people on other MS treatments. The goal is to find a new, non-invasive way…

This study is testing whether a program delivered remotely (by video or phone) that combines exercise and dementia caregiving support is practical and helpful for older adults with Down syndrome and their caregivers. About 40 participants will take part. The goal is to see if the…

This study is testing a new way to measure fatigue in people with spinal muscular atrophy (SMA), a condition that causes muscle weakness. The test is designed to be easy enough for patients with different levels of ability. Researchers want to see if the test is safe, doable, and…

This early study tests whether a brain implant can help people with severe paralysis from conditions like ALS, spinal cord injury, or stroke control devices using their thoughts. The implant records brain signals to decode text or synthesized speech. Only 3 adults will participat…

This study looks at whether treating depression with a common antidepressant (escitalopram) can change brain and blood markers linked to Alzheimer's disease. Researchers will compare the drug to a placebo in 60 adults aged 60 and older who have major depression but no memory prob…

This study is testing whether a non-invasive electrical stimulation technique can improve working memory, attention, and thinking skills in healthy older adults and those with mild cognitive impairment. The stimulation targets deep brain structures without surgery, using special …

This study at Mayo Clinic looks at two different types of Progressive Apraxia of Speech, a condition that makes it hard to speak clearly. Researchers will use brain scans, speech assessments, and thinking tests in 47 adults to better tell these types apart. The goal is to improve…

This study explores whether a non-invasive brain-computer interface (BCI) can help people with motor disorders, such as spinal cord injury or stroke, control assistive devices using their thoughts. Researchers will record brain signals with EEG and use machine learning to interpr…

This study looks at whether low levels of immunoglobulin G (IgG), a type of antibody, are linked to fatigue in people with multiple sclerosis (MS). Researchers will compare fatigue scores and infection rates between MS patients with low IgG and those with normal IgG. The goal is …

This study looks at how social and emotional thinking skills relate to everyday behavior in people with Alzheimer's disease and similar conditions. Researchers will give 120 participants tests of social cognition and ask their study partners to complete behavior checklists. They …

This study looks at whether simpler hearing aid settings work better for older adults with Alzheimer's dementia or mild memory problems. Researchers will test two different hearing aid programs in 20 participants to see which one helps them understand speech in noisy settings and…

This study is building a large registry of people with ALS in the United States. The goal is to count how many people have the disease and learn about possible causes, such as environmental or genetic factors. Anyone 18 or older with ALS can join. The registry does not test a tre…

This study follows about 300 people with Friedreich's ataxia who are taking the prescribed drug omaveloxolone (SKYCLARYS®). Researchers will collect safety information from regular doctor visits for up to 5 years. The goal is to see how many participants have serious side effects…

This study tests a 4-week training program for assisted living staff (nurses, administrators, and coordinators) to improve palliative care for residents with dementia. The goal is to increase advance care planning discussions and reduce caregiver burnout. About 792 participants f…